OVID THERAPEUTICS INC (OVID) Stock News
NASDAQ:OVID - Nasdaq - US6904691010 - Common Stock - Currency: USD
OVID Latest News, Press Relases and Analysis
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 0% and 96.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CVAC
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
Q1 earnings ...
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of 128.57% and 6.79%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: FTRE
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of 24.09% and 9.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ANIP
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ovid Therapeutics (NASDAQ:OVID) just reported results for the second quarter of...
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -62.75% and 8.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: JAZZ
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: IBRX
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares...
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule...
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for...
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for...
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding...
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Ovid Therapeutics to Host Investor Event
KCC2 Download Day on Wednesday, November 13, 2024
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of...
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
Ovid Therapeutics to Present at Upcoming September Investor Conferences
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of...
Ovid Therapeutics to Present at Upcoming September Investor Conferences
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded Scientific...
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ: OVID). Such investors...
Ovid Therapeutics to Present at Upcoming August Investor Conferences
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the...